Almotriptan is a selective 5-HT1B/1D receptor agonist (triptan) that constricts cranial blood vessels and inhibits pro-inflammatory neuropeptide release, providing targeted abortive therapy for acute migraine attacks. Simson Pharma's Almotriptan reference standard and impurities support stability-indicating assay work for this migraine-specific therapeutic class.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Almotriptan Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.